| Protein | Amino acid residue | VOC/VOI with this substitution as lineage-defining mutation (Date of designationa) | Patient number | 1st sequence with the respective substitutionc |
|---|---|---|---|---|
| NSP3 | 977 | Gamma (VOC: 2021-01-11) | P4 | July 2022 |
| P13 | September 2021 | |||
| P32 | October 2022 | |||
| NSP5 | 90 | Beta (VOC: 2020-12-18) | P9 | September 2021 |
| P10 | 2020 | |||
| P23 | March 2021 | |||
| NSP9 | 35 | EG.5 (VOI: 2023-08-09) BA.2.86 (VOI: 2023-11-21) JN.1 (VOI: 2023-12-18) |
P9 | September 2021 |
| P31 | November 2022 | |||
| P32 | July 2022 | |||
| P33 | October 2022 | |||
| NSP12 | 671 | Delta (VOC: 2021-05-11) XBB.1.5 (VOI: 2023-01-11) XBB.1.16 (VOI: 2023-04-17) |
P4 | August 2022 |
| P9 | September 2021 | |||
| P31 | February 2023 | |||
| S | 484 | Beta (VOC: 2020-12-18) Gamma (VOC: 2021-01-11) Omicron (VOC: 2021-11-26) Eta (VOI: 2021-03-17) Theta (VOI: 2021-03-24) Kappa (VOI: 2021-04-04) Mu (VOI: 2021-08-30) Zeta (VOI: 2021-09-17) XBB.1.5 (VOI: 2023-01-11) XBB.1.16 (VOI: 2023-04-17) EG.5 (VOI: 2023-08-09) BA.2.86 (VOI: 2023-11-21) JN.1 (VOI: 2023-12-18) |
P1 | June 2020 |
| P2 | June 2021 | |||
| P5 | October 2020 | |||
| P6 | February 2021 | |||
| P8 | May 2020 | |||
| P12 | November 2020 | |||
| P13 | June 2021 | |||
| P22 | July 2020 | |||
| P24 | February 2021 | |||
| P26 | June 2021 | |||
| 490 | Lambda (VOI: 2021-06-14) XBB.1.5 (VOI: 2023-01-11) XBB.1.16 (VOI: 2023-04-17) EG.5 (VOI: 2023-08-09) |
P2 | June 2021 | |
| P5 | December 2020 | |||
| P7 | December 2021 | |||
| P8 | May 2020 | |||
| P9 | September 2021 | |||
| P12 | November 2020 | |||
| P18 | N/A | |||
| 95 | Iota (VOI: 2021-03-24) Mu (VOI: 2021-08-30) Omicron (VOC: 2021-11-26)b |
P2 | June 2021 | |
| P6 | October 2021 | |||
| P7 | November 2021 | |||
| P17 | November 2021 | |||
| P18 | N/A | |||
| 493 | Omicron (VOC: 2021-11-26)e | P1 | August 2020 | |
| P7 | June 2021 | |||
| P25 | May 2021 | |||
| P26 | March 2021 | |||
| 13 | Epsilon (VOI: 2021-03-05) | P2 | June 2021 | |
| P3 | August 2020 | |||
| P8 | May 2020 | |||
| 417 | Beta (VOC: 2020-12-18) Gamma (VOC: 2021-01-11) Omicron (VOC: 2021-11-26)d XBB.1.5 (VOI: 2023-01-11) XBB.1.16 (VOI: 2023-04-17) EG.5 (VOI: 2023-08-09) BA.2.86 (VOI: 2023-11-21) JN.1 (VOI: 2023-12-18) |
P5 | December 2020 | |
| P21 | July 2022 | |||
| P24 | October 2022 | |||
| 440 | Omicron (VOC: 2021-11-26)d | P1 | September 2020 | |
| P28 | January 2021 | |||
| P33 | November 2022 | |||
| 450 | BA.2.86 (VOI: 2023-11-21) JN.1 (VOI: 2023-12-18) |
P9 | September 2021 | |
| P32 | September 2022 | |||
| P33 | October 2022 | |||
| 655 | Gamma (VOC: 2021-01-11) Omicron (VOC: 2021-11-26) XBB.1.5 (VOI: 2023-01-11) XBB.1.16 (VOI: 2023-04-17) EG.5 (VOI: 2023-08-09) BA.2.86 (VOI: 2023-11-21) JN.1 (VOI: 2023-12-18) |
P7 | December 2021 | |
| P10 | 2020 | |||
| P21 | June 2022 | |||
| M | 82 | Eta (VOI: 2021-03-17) Delta (VOI: 2021-04-04, VOC: 2021-05-11) Kappa (VOI: 2021-04-04) |
P2 | June 2021 |
| P7 | March 2021 | |||
| P10 | 2020 | |||
| P26 | August 2021 |
Abbreviations: F, female; M, male; VOC, variants of concern; VOI, variants of interest.
a
The dates of designation for the VOI and VOC were referenced from WHO's “Historical working definitions and primary actions for SARS-CoV-2 variants” document: https://www.who.int/publications/m/item/historical-working-definitions-and-primary-actions-for-sars-cov-2-variants and https://www.who.int/activities/tracking-SARS-CoV-2-variants/previously-circulating-vois.
b
Only in BA.1.
c
The dates that appear before the designation of the corresponding VOC/VOI by the WHO are Indicated in bold face.
d
Only in BA.2, BA.4, and BA.5.
e
Only BA.1 and BA.2.